Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Asset Writedowns and Impairment (2022 - 2023)

Historic Asset Writedowns and Impairment for ADC Therapeutics (ADCT) over the last 2 years, with Q4 2023 value amounting to $828000.0.

  • ADC Therapeutics' Asset Writedowns and Impairment fell 6170.74% to $828000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $1.6 million, marking a year-over-year decrease of 2572.75%. This contributed to the annual value of $1.5 million for FY2024, which is 559.7% down from last year.
  • Latest data reveals that ADC Therapeutics reported Asset Writedowns and Impairment of $828000.0 as of Q4 2023, which was down 6170.74% from $727000.0 recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Asset Writedowns and Impairment ranged from a high of $2.2 million in Q4 2022 and a low of $767.0 during Q3 2022